Navigation Links
International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
Date:3/20/2008

otrexate achieved at least a 50% (ACR50) reduction in symptoms compared to 10.8% of patients receiving placebo and methotrexate; ACR70 was achieved in 22% of the treatment group versus 2% in the control group. A rapid decrease in disease activity (DAS28)(2) was seen as early as two weeks in a greater proportion of patients treated with ACTEMRA plus methotrexate, with 27.5% achieving DAS28 less than or equal to 2.6 by 24 weeks.

Additionally, results showed that 80% of patients in the ACTEMRA (8mg/kg) plus methotrexate group responded with moderate to good improvements in RA symptoms, according to the EULAR response criteria(3), compared with 35% for those treated with placebo and methotrexate at 24 weeks. ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arms of the OPTION trial were upper respiratory tract infection, nasopharyngitis and headache.

The OPTION trial also assessed physical function and quality-of-life at baseline and every four weeks thereafter. Patients receiving ACTEMRA achieved significantly greater improvement in areas of fatigue and mental function at 24 weeks, and achieved normal levels of hemoglobin and C-reactive protein (CRP), a marker of inflammation due to RA, compared with patients receiving placebo plus methotrexate.

"We are very encouraged by the findings of the study as they further establish the role of ACTEMRA and its unique blockade of IL-6 receptors as a potential new biologic treatment option for patients with RA," said Lars Birgerson, M.D., Ph.D, Vice President, Global Head Medical Affairs, Roche.

About ACTEMRA(TM) (tocilizumab)

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody. Studies suggest that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints and relieve certain systemic effects of RA. The extensive clinical
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
3. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
6. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
10. Survival Data for Avicenas Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND
11. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... March 6, 2015 Ultra Clean ... Intuitive Surgical, the manufacturer of da Vinci® ... Cleaning System. This approval reflects the unit,s ability ... currently in place for the sterile processing industry. ... reprocessing robotic surgical instruments for re-use. ...
(Date:3/6/2015)... 2015  The German Court of Appeal has ruled that ... regimen patent for Alimta® (pemetrexed disodium) would not be infringed ... salt form of pemetrexed in Germany ... The German Court ruled in favor of the generic ... Actavis. This decision vacated the prior decision of the Regional ...
(Date:3/6/2015)... , Alemania, 6 de marzo de 2015 /PRNewswire/ ... soluciones de gestión empresarial de imagen médica, fortalece ... el nombramiento de Randolph Sternberg como ... como director de operaciones. Logo ... Sternberg será responsable de las ventas y ...
Breaking Medicine Technology:Ultra Clean Systems Reaches Exclusive Place within Robotic Surgical Instrument Cleaning Industry with Latest Certifications 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 2German Court Rules Against Lilly in Alimta Vitamin Regimen Patent Lawsuit 3TeraRecon fortalece su posición en EMEA 2TeraRecon fortalece su posición en EMEA 3
... New Oral, Once-Daily Direct Factor Xa Inhibitor,Shows ... and Pulmonary,Embolism Compared with Enoxaparin with Similarly ... - Late-breaking Phase III clinical trial,data presented ... Thrombosis,and Haemostasis (ISTH) Congress demonstrate that once-daily,rivaroxaban ...
... Massachusetts, July 08, 2007 /PRNewswire/ -- , ... to Urgently,Implement Hospital-Wide Strategies to Optimize VTE ... Provide Appropriate,prophylaxis to Prevent VTE , Venous ... and most of these at-risk patients are ...
Cached Medicine Technology:Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 2Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 3Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 4Phase III Trial Results Show Superiority of Rivaroxaban over,Enoxaparin for the Prevention of Venous Thromboembolism in Patients,Undergoing Knee Replacement Surgery 5International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 2International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 3International ENDORSE Study Shows That the Majority of Hospitalized,Patients Surveyed are at Risk for VTE and Many do not Receive,Recommended VTE prophylaxis 4
(Date:3/6/2015)... (PRWEB) March 06, 2015 As the ... healthcare services programs, the organization has hired two new ... Ph.D. They will report to Grace Pavlath, Ph.D, ... President and Scientific Program Director, and together will lead ... to treatments and cures for various types of neuromuscular ...
(Date:3/6/2015)... 2015 “On Tap” takes the audience on ... stage, to the silver screen and to modern day rhythm ... numbers and their famous eye-high kicks! Producers, directors and choreographers ... of tap dancing in this robust show, showcasing one of ... United States. , “On Tap” is proud to host ...
(Date:3/6/2015)... 06, 2015 US Sports Football Camps ... camps – two non-contact specialty camps and one contact ... Perfect Performance Training, located at Bowie State University and ... position specific skills, speed and strength of football athletes. ... University with Marvin Graves, former quarterback in the Canadian ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 At ... company, announced today the launch of its powerful, ... on healthy and sustainable products at any retailer ... is exhibiting at Expo West Booth 6054. ... by gluten-free, Kosher, non-GMO, organic, Paleo, and vegan, ...
(Date:3/6/2015)... March 06, 2015 Johnson & Johnson ... verdict on March 5, 2015 in Superior Court in ... court documents, a jury of 12 awarded Mrs. Perry ... being implanted with an Ethicon TVT Abbrevo plastic sling ... and three women also awarded $5 million in punitive ...
Breaking Medicine News(10 mins):Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 2Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 3Health News:MDA Adds Muscle Disease and ALS Leaders to Research Team 4Health News:The Legacy Dancers, a Dazzling Dance Troupe of Former Rockettes, Kick to New Heights in “On Tap: From Broadway to the Silver Screen” 2Health News:US Sports Camps to Host Three New Football Camps in Maryland 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 2Health News:Makeena Launches App that Makes Healthy and Sustainable Products More Affordable for Shoppers 3Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 2Health News:Johnson & Johnson Hit with $5.7 Million Verdict in Pelvic Mesh Trial Announces Matthews & Associates Law Firm 3
... , TUESDAY, Feb. 8 (HealthDay News) -- Heavy drinking ... and is associated with long-term alcohol-related problems, researchers warn. ... drinking among older teens not only prevents immediate harm, ... the study authors pointed out. The researchers reviewed ...
... slightly higher in the offspring of male cancer survivors ... cancer, according to a study published online February 8th ... The increasing number of male cancer survivors ... their offspring. Although previous studies on children conceived naturally ...
... -- Researchers at the University at Buffalo have devised ... these medically important molecules from losing their shape and ... help speed the development of peptide-based drugs against diseases ... are simpler than existing techniques, one of which employs ...
... (HealthDay News) -- People whose genetic make-up produces lower levels ... at increased risk for major depression, says a new study. ... down after experiencing stressful events. This study found that ... cause them to produce lower levels of NPY have stronger ...
... (HealthDay News) -- Babies who are exposed to HIV at ... levels of antibodies to diseases such as whooping cough, tetanus ... samples from 104 HIV-infected and uninfected South African women and ... of the infants at 16 weeks of age. The samples ...
... beneath the surface, a team of researchers from the ... three South Korean institutions have identified two distinct neuronal ... treat a variety of skin diseases. One pathway produces ... a side effect. The findings, published in this ...
Cached Medicine News:Health News:Male cancer survivor offspring slightly higher risk of congenital birth abnormalities 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:Study Links Brain Molecule to Risk of Major Depression 2Health News:Mom's HIV May Lower Baby's Immunity to Other Diseases 2Health News:The hitch in the drug? The itch in the drug 2
... was developed to address hematology needs ... of use, low maintenance, closed-tube sampling, ... are features expected in the modern ... fast access to results, sophisticated data ...
Inquire...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: